News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Supervisory Board intends to appoint Michael Brunner and Heinz Hoffmann as members of the Management Board of Einhell Germany AG effective January 1, 2026
Supervisory Board of Einhell Germany AG intends to appoint Michael Brunner and Heinz Hoffmann as members of the Management Board effective January 1, 2026, succeeding Mr. Jan Teichert -
COMMUNIQUÉ DE PRESSE
55 North Mining Announces Upcoming 2026 Drill Program - Winter Drilling May Commence in Late 2025 Pending Weather Conditions
55 North Mining Inc. provides an update on its 2026 drill program, focusing on step-out drilling to expand known mineralization. Winter drilling may start in late 2025. Drilling costs estimated at $250 per metre -
COMMUNIQUÉ DE PRESSE
Partners Group to acquire Life Cycle Power, a leading provider of mobile generation solutions in the US
Partners Group to acquire Life Cycle Power, a leading provider of mobile generation solutions in the US. The acquisition aims to expand mobile power solutions for data center and industrial customers -
COMMUNIQUÉ DE PRESSE
NuRAN Wireless Announces Adjournment of its Annual General and Special Meeting
NuRAN Wireless Inc. announces the adjournment of its Annual General and Special Meeting to provide more disclosure for stakeholders. Leading rural telecommunications company bridging the digital divide -
-
COMMUNIQUÉ DE PRESSE
Athena Bitcoin Wins Juniper Research 2025 Fintech & Payments Gold Award for Digital Currency Innovation
Athena Bitcoin Global wins Juniper Research's 2025 Fintech & Payments Gold Award for Digital Currency Innovation, recognizing its commitment to digital payments and financial inclusion -
COMMUNIQUÉ DE PRESSE
NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
NanoViricides, Inc. reveals dual-track clinical development strategy for NV-387 targeting respiratory viral infections including Influenzas, Coronaviruses, RSV. Analyst report details trials and future prospects
